At a glance
ClinicalIndex Comparison RecordPhase 3Unknown· 1,800 enrolled
Drug / intervention
Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SYNTAX Study: SYNergy Between PCI With TAXUS and Cardiac Surgery
In Brief
A Phase 3 clinical trial evaluating Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent and Coronary Artery Bypass Surgery for Coronary Artery Disease. Targeting 1,800 participants across 106 sites in 18 countries.
Detailed Summary
The SYNTAX trial is designed to determine the best treatment for patients with complex coronary disease (blocked or narrowed arteries in both the right and left sides of the heart) by randomizing patients to receive either percutaneous coronary intervention (PCI) with polymer-based paclitaxel-eluting TAXUS stents or to coronary artery bypass surgery (CABG).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesAustria, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Latvia, Netherlands, Norway, Poland, Portugal, Spain, Sweden, United Kingdom, United States
CollaboratorsCardialysis BV
Timeline
Phase 3UnknownOverdue
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2005
First PostedJun 2005
Primary CompletionApr 2008
Study CompletionMay 2012
TodayJul 2026
First PostedJun 21, 2005
Enrollment StartMar 1, 2005
Primary CompletionApr 1, 2008
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 21.0 years ago
Interventions
Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stentdevice
Drug Eluting Stent
Coronary Artery Bypass Surgeryprocedure
Coronary Artery Bypass Surgery